Vasoactive intracavernous pharmacotherapy

Urol Clin North Am. 1988 Feb;15(1):95-101.

Abstract

The use of vasoactive intracavernous pharmacotherapy for the treatment of impotence is rapidly expanding because of its effectiveness and the rarity of short-term complications. To minimize complications, careful selection of candidates, cautious dosage determination, and thorough instruction on injection technique are mandatory. Sustained erection should be treated with alpha-adrenergic agents after 4 to 6 hours. Frequent follow-up is mandatory after home injection begins to detect the development of penile abnormalities. Longer follow-up and additional studies are required to determine the types and incidences of long-term adverse effects of the technique.

Publication types

  • Review

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / physiopathology
  • Follow-Up Studies
  • Humans
  • Injections / adverse effects
  • Injections / methods
  • Male
  • Papaverine / administration & dosage*
  • Papaverine / adverse effects
  • Penile Erection / drug effects
  • Penis
  • Phentolamine / administration & dosage
  • Phentolamine / adverse effects
  • Phentolamine / analogs & derivatives*
  • Self Administration
  • Time Factors
  • Vasomotor System / drug effects*

Substances

  • Papaverine
  • Phentolamine